NCI Director and Acting FDA Commissioner Andrew von Eschenbach Endorses Rep. E. Clay Shaw In Tour of Florida Congressman’s District. Von Eschenbach Praises Shaw’s “Leadership” In Seeking Funding For Research, Support of 2015 Goal.
Shaw’s Lung Cancer, Bronchoalveolar Carcinoma, Exemplifies Elusiveness of 2015 Goal. Little Known About The Rare Disease.
Also In This 12-page Issue: NCI To Cut Budgets For New Grants By 29 Percent. R01s To Be Funded At 11th Percentile.
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored









